Nathan B. Mantlo
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Peroxisome Proliferator-Activated Receptors, Synthetic Organic Chemistry Methods, Pharmacogenetics and Drug Metabolism, Renin-Angiotensin System Studies
Most-Cited Works
- → Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase(1997)333 cited
- → Potent, orally absorbed glucagon receptor antagonists(1999)169 cited
- → Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists(1991)161 cited
- → Pyrroles and other heterocycles as inhibitors of P38 kinase(1998)117 cited
- → Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure(2011)115 cited
- → Substituted Imidazoles as Glucagon Receptor Antagonists(2001)108 cited
- → Total synthesis of calicheamicinone: new arrangements for actuation of the reductive cycloaromatization of aglycon congeners(1991)107 cited
- → In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.(1992)107 cited
- → In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.(1992)95 cited
- → Effects of Subtype-Selective and Balanced Angiotensin II Receptor Antagonists in a Porcine Coronary Artery Model of Vascular Restenosis(1996)69 cited